Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled trial of melatonin as an add-on
therapy to antipsychotics will be performed to examine the effects of melatonin on tardive
dyskinesia symptoms and cognitive deficits in 120 patients with established tardive
dyskinesia (TD). This study addresses a free radical hypothesis of TD.